Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

647690.pdf (1.35 MB)

Document type

Article

Version

Accepted version

Publication date

2015-01-01

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/140650

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3233/JAD-141014

Abstract

Several recent findings suggest that targeting the endogenous cannabinoid system can be considered as a potential therapeutic approach to treat Alzheimer's disease (AD). The present study supports this hypothesis demonstrating that delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids, which are the components of an already approved cannabis-based medicine, preserved memory in AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Moreover, THC + CBD reduced learning impairment in AβPP/PS1 mice. A significant decrease in soluble Aβ42 peptide levels and a change in plaques composition were also observed in THC + CBD-treated AβPP/PS1 mice, suggesting a cannabinoid-induced reduction in the harmful effect of the most toxic form of the Aβ peptide. Among the mechanisms related with these positive cognitive effects, the anti-inflammatory properties of cannabinoids may also play a relevant role. Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AβPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD. Moreover, other cannabinoid-induced effects were uncovered by a genome-wide gene expression study. Thus, we have identified the redox protein thioredoxin 2 and the signaling protein Wnt16 as significant substrates for the THC + CBD-induced effects in our AD model. In summary, the present findings show that the combination of THC and CBD exhibits a better therapeutic profile than each cannabis component alone and support the consideration of a cannabis-based medicine as potential therapy against AD.

Subject

Malaltia d'Alzheimer, Pèptids, Cervell, Efectes secundaris dels medicaments, Marihuana, Farmacologia, Plaquetes sanguínies, Metabolisme

Subject (English)

Alzheimer's disease, Peptides, Brain, Drug side effects, Marijuana, Pharmacology, Blood platelets, Metabolism

Citation

Collections

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Genètica, Microbiologia i Estadística)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

ASO PÉREZ, Ester, et al. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. Journal of Alzheimer's Disease. 2015. Vol. 43, num. 3, pags. 977-991. ISSN 1387-2877. [consulted: 17 of August of 2026]. Available at: https://hdl.handle.net/2445/140650

Export metadata

JSON - METS

Share record